Testing the SurVaxM Vaccine for Lung Cancer Prevention

Conditions

• Lung Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo collection of blood samples
• Montanide ISA 51 VG — DRUG
  Given SC
• Questionnaire Administration — OTHER
  Ancillary studies
• Sargramostim — BIOLOGICAL
  Given SC
• SVN53-67/M57-KLH Peptide Vaccine — BIOLOGICAL
  Given SC

Study Details

This phase II trial tests how well a survivin peptide vaccine called SurVaxM works in preventing lung cancer in high risk patients. Upon administration, the SurVaxM vaccine activates the immune system to produce an immune cell response against cancer cells that express a protein called survivin. This may result in decreased tumor cell proliferation and lead to tumor cell death. SurVaxM is given with montanide, a substance that helps the immune system respond to the SurVaxM vaccine, followed by sargramostim, which is given to increase the number of white blood cells in the body. The SurVaxM vaccine may help the body make special proteins called antibodies, which may be helpful in preventing the development of lung cancer.

Key Dates

Start date

Jul 1, 2026

Status verified

Jun 2026

Primary completion

Mar 30, 2029

Completion

Sep 30, 2029

Study Design

Enrollment

80 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Arms

• Experimental: Prevention (SurVaxM, montanide, sargramostim)
  Patients receive SurVaxM with montanide SC followed by sargramostim SC on day 0, week 2, week 4, and week 6. Patients then receive a booster dose of SurVaxM with montanide SC followed by sargramostim SC on week 18. Patients also undergo collection of blood samples throughout the trial.

Primary Outcome Measure

Seroconversion rate [ Time Frame: Up to week 20 ]

Locations (4)

Find similar trials in Aurora, CO

Related Studies

• Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
  Recruiting · Northwestern University · Chicago, Illinois
• Lung Cancer Screening in High-risk Black Individuals
  Recruiting · Massachusetts General Hospital · Chicago, Illinois
• Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
  Recruiting · City of Hope Medical Center · Davis, California
• The Vanguard Study: Testing a New Way to Screen for Cancer
  Recruiting · National Cancer Institute (NCI) · Pleasanton, California